An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB-c miceReportar como inadecuado

An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB-c mice - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Immunity and Ageing

, 9:21

First Online: 02 October 2012Received: 08 August 2012Accepted: 28 September 2012


BackgroundRespiratory Syncytial Virus RSV causes significant disease in the elderly, in part, because immunosenescence impairs protective immune responses to infection in this population. Despite previous and current efforts, there is no RSV vaccine currently licensed in infants or elderly adults. Adjuvanted RSV subunit vaccines have the potential to boost waning immune responses and reduce the burden of RSV disease in the elderly population.

ResultsWe used an aged BALB-c mouse model to evaluate immune responses to RSV Fusion F protein in the absence and presence of an alum adjuvant. We demonstrate that aged BALB-c mice immunized with alum-adjuvanted RSV F protein had significantly reduced lung viral titers at day 4 following challenge with wild-type wt RSV. Serum neutralizing antibody titers measured on day 27 correlated with protection in both young and aged vaccinated mice, although the magnitude of antibody titers was lower in aged mice. Unlike young mice, in aged mice, alum-adjuvanted RSV F did not induce lung TH2-type cytokines or eosinophil infiltration compared to non-adjuvanted F protein following wt RSV challenge.

ConclusionOur studies demonstrate that neutralizing anti-RSV antibody titers correlate with protection in both young and aged BALB-c mice vaccinated with RSV F protein vaccines. The F + alum formulation mediated greater protection compared to the non-adjuvanted F protein in both young and aged mice. However, while alum can boost F-specific antibody responses in aged mice, it does not completely overcome the reduced ability of a senescent immune system to respond to the RSV F antigen. Thus, our data suggest that a stronger adjuvant may be required for the prevention of RSV disease in immunosenescent populations, to achieve the appropriate balance of protective neutralizing antibodies and effective TH1-type cytokine response along with minimal lung immunopathology.

KeywordsRespiratory Syncytial Virus Immunosenescence Alum Adjuvant Aged mice AbbreviationsRSVRespiratory Syncytial Virus

AlumAluminum Hydroxide

GFPGreen Fluorescent Protein


Electronic supplementary materialThe online version of this article doi:10.1186-1742-4933-9-21 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Anu Cherukuri - Kate L Stokes - Kathryn Patton - Howard Kuo - Kaori Sakamoto - Stacie Lambert - Elizabeth Stillman - Marti


Documentos relacionados